[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:brca1-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"BRCA1 Gene",68,55,[8,16,23,29,36,42,48,54,60,66,72,78,84,90,96,102,108,114,120,126,132,138,144,150,156,161,167,172,178,183,190,196,202,208,214,220,226,232,238,243,249,255,261,267,272,277,283,289,295,301],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06236139","Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:15:45.413021Z","2026-07-05T05:32:16.748678Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06844383","A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate",[20],"Phase 2","2026-08-26T02:17:43.321968Z","2026-05-05T02:43:29.708217Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT03990896","Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial",[20],"2026-08-26T02:16:57.705506Z","2026-05-05T02:43:29.705241Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT04150042","SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells",[33],"Phase 1","2026-08-26T02:18:58.141497Z","2026-05-05T02:43:29.297862Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT04858334","APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation",[20],"2026-08-26T02:15:52.238965Z","2026-05-05T02:43:29.056915Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT06267729","Study of AZD0754 in Participants With Metastatic Prostate Cancer",[12],"2026-08-26T02:16:55.892527Z","2026-05-05T02:43:28.077996Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT04090567","Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer",[20],"2026-08-26T02:15:23.202838Z","2026-05-05T02:43:27.963659Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":52,"content_modified":59},"NCT06380751","Saruparib (AZD5305) Plus Camizestrant Compared With CDK4\u002F6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+\u002F ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer",[58],"Phase 3","2026-05-05T02:43:27.920406Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT05687110","Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes",[33],"2026-08-26T02:17:58.890423Z","2026-05-05T02:43:27.808389Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT06177171","Olaparib and ASTX727 in BRCA1\u002F2- and Homologous Recombination Deficient (HRD)-Mutated Tumors",[33],"2026-08-26T02:17:22.949982Z","2026-05-05T02:43:27.676733Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT06488378","Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1\u002F2 and PALB2- Associated Metastatic HER2-negative Breast Cancer",[33],"2026-08-26T02:16:07.529922Z","2026-05-05T02:43:27.482798Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT05806515","Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation",[20],"2026-08-26T02:17:07.954622Z","2026-05-05T02:43:27.295281Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT06632977","Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial",[20],"2026-08-26T02:19:23.493898Z","2026-05-05T02:43:27.248700Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT06952803","A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT\u002FADT in Men With High-risk Prostate Cancer With a BRCA Mutation",[58],"2026-08-26T02:15:39.267524Z","2026-05-05T02:43:26.975819Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT03786796","Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations",[20],"2026-08-26T02:18:38.077159Z","2026-05-05T02:35:31.766251Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT07213804","A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer",[58],"2026-08-26T02:17:27.435233Z","2026-07-05T05:32:16.660912Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT06580314","Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer",[58],"2026-08-26T02:16:52.995882Z","2026-05-05T02:43:29.331227Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT05694715","Combination Therapy in Cancers With Mutations in DNA Repair Genes",[33],"2026-08-26T02:16:34.792807Z","2026-05-05T02:43:28.876459Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":124,"content_modified":125},"NCT05700721","Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)",[20],"2026-08-26T02:19:26.493949Z","2026-05-05T02:43:26.981975Z",{"nct_id":127,"title":128,"phases":129,"status":13,"updated_at":130,"content_modified":131},"NCT06458712","Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies",[33],"2026-08-26T02:15:51.395565Z","2026-07-24T01:27:14.872137Z",{"nct_id":133,"title":134,"phases":135,"status":13,"updated_at":136,"content_modified":137},"NCT05417594","Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies",[12],"2026-08-26T02:18:54.586325Z","2026-05-05T02:43:28.529406Z",{"nct_id":139,"title":140,"phases":141,"status":13,"updated_at":142,"content_modified":143},"NCT04890613","Study of CX-5461 in Patients With Solid Tumours and BRCA1\u002F2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation",[33],"2026-08-26T02:17:39.048487Z","2026-05-05T02:43:27.067991Z",{"nct_id":145,"title":146,"phases":147,"status":13,"updated_at":148,"content_modified":149},"NCT05841563","Clinical Trial of PM54 in Advanced Solid Tumors Patients.",[33],"2026-08-26T02:15:18.897219Z","2026-05-05T02:43:26.706220Z",{"nct_id":151,"title":152,"phases":153,"status":13,"updated_at":154,"content_modified":155},"NCT05287451","Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study",[],"2026-08-26T02:15:44.309045Z","2026-07-05T05:32:16.798306Z",{"nct_id":157,"title":158,"phases":159,"status":13,"updated_at":82,"content_modified":160},"NCT04251052","A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer",[],"2026-05-05T02:43:27.816245Z",{"nct_id":162,"title":163,"phases":164,"status":13,"updated_at":165,"content_modified":166},"NCT04294927","TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention",[],"2026-08-26T02:15:25.633039Z","2026-05-05T02:43:27.631193Z",{"nct_id":168,"title":169,"phases":170,"status":13,"updated_at":64,"content_modified":171},"NCT04913064","Effects of White Button Mushroom on Inflammation in Obese Postmenopausal Women at High Risk of Breast Cancer",[],"2026-05-05T02:43:27.487085Z",{"nct_id":173,"title":174,"phases":175,"status":13,"updated_at":176,"content_modified":177},"NCT05013216","Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer",[33],"2026-08-26T02:16:23.080181Z","2026-05-05T02:43:26.738998Z",{"nct_id":179,"title":180,"phases":181,"status":13,"updated_at":124,"content_modified":182},"NCT05384535","Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort",[],"2026-05-05T02:43:28.342933Z",{"nct_id":184,"title":185,"phases":186,"status":13,"updated_at":188,"content_modified":189},"NCT06122896","Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals",[187],"Early Phase 1","2026-08-26T02:17:13.277148Z","2026-05-05T02:43:27.075591Z",{"nct_id":191,"title":192,"phases":193,"status":13,"updated_at":194,"content_modified":195},"NCT03729115","A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer",[],"2026-08-26T02:18:11.042248Z","2026-05-05T02:43:26.901351Z",{"nct_id":197,"title":198,"phases":199,"status":13,"updated_at":200,"content_modified":201},"NCT02000089","The Cancer of the Pancreas Screening-5 CAPS5)Study",[58],"2026-08-26T02:17:20.511551Z","2026-05-05T02:43:27.641158Z",{"nct_id":203,"title":204,"phases":205,"status":13,"updated_at":206,"content_modified":207},"NCT04494945","Identifying and Caring for Individuals With Inherited Cancer Syndrome",[],"2026-08-26T02:17:39.857430Z","2026-05-05T02:35:31.687767Z",{"nct_id":209,"title":210,"phases":211,"status":13,"updated_at":212,"content_modified":213},"NCT07612046","A Study of Magnetic Resonance Imaging of the Pancreas for Cancer Screening",[],"2026-08-26T02:16:27.227548Z","2026-07-19T19:36:05.076756Z",{"nct_id":215,"title":216,"phases":217,"status":13,"updated_at":218,"content_modified":219},"NCT07197723","Study of How People Make Decisions About Prostate Cancer Risk",[],"2026-08-26T02:18:04.640417Z","2026-07-19T19:36:05.065373Z",{"nct_id":221,"title":222,"phases":223,"status":13,"updated_at":224,"content_modified":225},"NCT03396341","Responses to Genetic Risk Modifier Testing Among Women With Pathogenic Variants in Breast Cancer Predisposition Genes",[],"2026-08-26T02:16:12.203827Z","2026-07-05T05:32:16.770025Z",{"nct_id":227,"title":228,"phases":229,"status":13,"updated_at":230,"content_modified":231},"NCT07645391","Targeted Early Detection Program in Men at High Genetic Risk for Prostate Cancer",[],"2026-08-26T02:16:05.813655Z","2026-06-14T18:39:22.265063Z",{"nct_id":233,"title":234,"phases":235,"status":13,"updated_at":236,"content_modified":237},"NCT07038785","Identification of Breast Cancer in Breath Samples Using Trained Detection Dogs",[],"2026-08-26T02:18:38.865010Z","2026-05-13T02:55:06.608906Z",{"nct_id":239,"title":240,"phases":241,"status":13,"updated_at":64,"content_modified":242},"NCT06888388","Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer",[],"2026-05-13T02:55:06.588403Z",{"nct_id":244,"title":245,"phases":246,"status":13,"updated_at":247,"content_modified":248},"NCT06271291","Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts",[],"2026-08-26T02:18:36.226508Z","2026-05-13T02:55:06.430707Z",{"nct_id":250,"title":251,"phases":252,"status":13,"updated_at":253,"content_modified":254},"NCT05129605","Prostate Cancer Genetic Risk Evaluation and Screening Study",[],"2026-08-26T02:18:25.327036Z","2026-05-13T02:55:06.292506Z",{"nct_id":256,"title":257,"phases":258,"status":13,"updated_at":259,"content_modified":260},"NCT05058846","Pilot Study of Pancreatic Cancer Screening",[],"2026-08-03T02:54:15.542480Z","2026-05-13T02:55:06.282505Z",{"nct_id":262,"title":263,"phases":264,"status":13,"updated_at":265,"content_modified":266},"NCT05006131","Pancreatic Cancer Screening for At-risk Individuals",[],"2026-08-26T02:17:12.307088Z","2026-05-13T02:55:06.277680Z",{"nct_id":268,"title":269,"phases":270,"status":13,"updated_at":212,"content_modified":271},"NCT04794322","Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer",[],"2026-05-13T02:55:06.270061Z",{"nct_id":273,"title":274,"phases":275,"status":13,"updated_at":148,"content_modified":276},"NCT03805919","Men at High Genetic Risk for Prostate Cancer",[],"2026-05-13T02:55:06.177945Z",{"nct_id":278,"title":279,"phases":280,"status":13,"updated_at":281,"content_modified":282},"NCT03250078","A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals",[],"2026-08-26T02:16:58.658552Z","2026-05-13T02:55:06.120432Z",{"nct_id":284,"title":285,"phases":286,"status":13,"updated_at":287,"content_modified":288},"NCT02478892","Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk",[],"2026-08-26T02:19:21.761002Z","2026-05-13T02:55:06.095979Z",{"nct_id":290,"title":291,"phases":292,"status":13,"updated_at":293,"content_modified":294},"NCT07564141","Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer",[58],"2026-08-26T02:16:39.977107Z","2026-07-19T19:36:05.140343Z",{"nct_id":296,"title":297,"phases":298,"status":13,"updated_at":299,"content_modified":300},"NCT04970056","Pancreatic Cancer Early Detection Consortium",[],"2026-08-26T02:15:04.877798Z","2026-05-13T02:55:06.276618Z",{"nct_id":302,"title":303,"phases":304,"status":13,"updated_at":305,"content_modified":306},"NCT01102556","PANCREATIC DISEASE COHORT A Registry and Biospecimen Bank to Better Understand Pancreatic Disease",[],"2026-08-26T02:19:07.104270Z","2026-05-13T02:55:06.068743Z"]